One year prospective survey of Candida bloodstream infections in Scotland

Journal of Medical Microbiology

Volumn 56, Issue 8, 2007, Pages 1066-1075

  Odds, Frank C ^a   Hanson, Mary F ^b   Davidson, Amanda D ^a   Jacobsen, Mette D ^a   Wright, Pauline ^c   Whyte, Julie A ^a   Gow, Neil A R ^a   Jones, Brian L ^c  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

^b WESTERN GENERAL HOSPITAL   (United Kingdom)

^c GLASGOW ROYAL INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; CASPOFUNGIN; FLUCONAZOLE; FLUCYTOSINE; ITRACONAZOLE; VORICONAZOLE;

ADOLESCENT; ADULT; AGED; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL INFECTION; CANDIDA; CANDIDA ALBICANS; CANDIDA DUBLINIENSIS; CANDIDA GLABRATA; CANDIDA LUSITANIAE; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS; CANDIDEMIA; CANDIDIASIS; CHILD; FEMALE; FUNGAL STRAIN; FUNGUS ISOLATION; HOSPITAL LABORATORY; HUMAN; INCIDENCE; INDWELLING CATHETER; INTENSIVE CARE UNIT; INTRAVENOUS CATHETER; LAPAROTOMY; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; MYCOSIS; NONHUMAN; POPULATION RESEARCH; PRIORITY JOURNAL; PROSPECTIVE STUDY; UNITED KINGDOM;

ADOLESCENT; ADULT; AGED; ANTIFUNGAL AGENTS; BACTERIAL INFECTIONS; CANDIDA; CANDIDIASIS; CATHETERS, INDWELLING; CHILD; CHILD, PRESCHOOL; FEMALE; FLUCONAZOLE; FUNGEMIA; HEALTH SURVEYS; HUMANS; INCIDENCE; INFANT; LAPAROTOMY; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MYCOLOGICAL TYPING TECHNIQUES; PROSPECTIVE STUDIES; RISK FACTORS; SCOTLAND;

EID: 34547877230     PISSN: 00222615     EISSN: None     Source Type: Journal    
DOI: 10.1099/jmm.0.47239-0     Document Type: Article

References (59)

1. Almirante, B., Rodriguez, D., Park, B. J., Cuenca-Estrella, M., Planes, A. M., Almela, M., Mensa, J., Sanchez, F., Ayats, J. & other authors (2005). Epidemiology and predictors of mortality in cases of Candida bloodstream infection: results from population-based surveillance, Barcelona, Spain, from 2002 to 2003. J Clin Microbiol 43, 1829-1835.
2. Andes, D. (2004). Antifungal pharmacokinetics and pharmacodynamics: understanding the implications for antifungal drug resistance. Drug Resist Updat 7, 185-194.
3. Andes, D. & van Ogtrop, H. (1999). Characterization and quantitation of the pharmacodynamics of fluconazole in a neutropenic murine disseminated candidiasis infection model. Antimicrob Agents Chemother 43, 2116-2120.
4. HPA (2004). Candidaemia reports, England, Wales, and Northern Ireland: 2003. CDR Weekly 14, 1-3. http://www.hpa.org.uk/cdr/ archives/2004/cdr4304.pdf
5. Arendrup, M. C., Fuursted, K., Gahrn-Hansen, B., Jensen, I. M., Knudsen, J. D., Lundgren, B., Schonheyder, H. C. & Tvede, M. (2005). Seminational surveillance of fungemia in Denmark: notably high rates of fungemia and numbers of isolates with reduced azole susceptibility. J Clin Microbiol 43, 4434-4440.
6. Arthington-Skaggs, B. A., Lee-Yang, W., Ciblak, M. A., Frade, J. P., Brandt, M. E., Hajjeh, R. A., Harrison, L. H., Sofair, A. N. & Warnock, D. W. (2002). Comparison of visual and spectrophotometric methods of broth microdilution MIC end point determination and evaluation of a sterol quantitation method for in vitro susceptibility testing of fluconazole and itraconazole against trailing and nontrailing Candida isolates. Antimicrob Agents Chemother 46, 2477-2481.
7. Asmundsdottir, L. R., Erlendsdottir, H. & Gottfredsson, M. (2002). Increasing incidence of candidemia: results from a 20-year nationwide study in Iceland. J Clin Microbiol 40, 3489-3492.
8. Bassetti, M., Righi, E., Costa, A., Fasce, R., Molinari, M. P., Rosso, R., Pallavicini, F. B. & Viscoli, C. (2006). Epidemiological trends in nosocomial candidemia in intensive care. BMC Infect Dis 6, 21.
9. Blignaut, E., Pujol, C., Lockhart, S., Joly, S. & Soll, D. R. (2002). Ca3 fingerprinting of Candida albicans isolates from human immunodeficiency virus-positive and healthy individuals reveals a new clade in South Africa. J Clin Microbiol 40, 826-836.
10. Blijlevens, N. M. A., Donnelly, J. P. & de Pauw, B. E. (2002). Impaired gut function as risk factor for invasive candidiasis in neutropenic patients. Br J Haematol 117, 259-264.
11. Blumberg, H. M., Jarvis, W. R., Soucie, J. M., Edwards, J. E., Patterson, J. E., Pfaller, M. A., Rangel-Frausto, M. S., Rinaldi, M. G., Saiman, L. & other authors (2001). Risk factors for candidal bloodstream infections in surgical intensive care unit patients: the NEMIS prospective multicenter study. Clin Infect Dis 33, 177-186.
12. Bougnoux, M. E., Tavanti, A., Bouchier, C., Gow, N. A. R., Magnier, A., Davidson, A. D., Maiden, M. C. J., d'Enfert, C. & Odds, F. C. (2003). Collaborative consensus for optimized multilocus sequence typing of Candida albicans. J Clin Microbiol 41, 5265-5266.
13. Chan-Tack, K. M. (2005). Fatal Candida dubliniensis septicemia in a patient with AIDS. Clin Infect Dis 40, 1209-1210.
14. Cohen, R., Roth, F. J., Delgado, E., Ahearn, D. G. & Kalser, M. H. (1969). Fungal flora of the normal human small and large intestine. N Engl J Med 280, 638-641.
15. Cuenca-Estrella, M., Rodero, L., Garcia-Effron, G. & Rodriguez-Tudela, J. L. (2002a). Antifungal susceptibilities of Candida spp. isolated from blood in Spain and Argentina, 1996-1999. J Antimicrob Chemother 49, 981-987.
16. Cuenca-Estrella, M., Lee-Yang, W., Ciblak, M. A., Arthington-Skaggs, B. A., Mellado, E., Warnock, D. W. & Rodriguez-Tudela, J. L. (2002b). Comparative evaluation of NCCLS M27-A and EUCAST broth microdilution procedures for antifungal susceptibility testing of Candida species. Antimicrob Agents Chemother 46, 3644-3647.
17. Cuenca-Estrella, M., Moore, C. B., Barchiesi, F., Bille, J., Chryssanthou, E., Denning, D. W., Donnelly, J. P., Dromer, F., Dupont, B. & other authors (2003). Multicenter evaluation of the reproducibility of the proposed antifungal susceptibility testing method for fermentative yeasts of the Antifungal Susceptibility Testing Subcommittee of the European Committee on Antimicrobial Susceptibility Testing (AFST-EUCAST). Clin Microbiol Infect 9, 467-474.
18. Cuenca-Estrella, M., Gomez-Lopez, A., Mellado, E. & Rodriguez-Tudela, J. L. (2005). Correlation between the procedure for antifungal susceptibility testing for Candida spp. of the European Committee on Antibiotic Susceptibility Testing (EUCAST) and four commercial techniques. Clin Microbiol Infect 11, 486-492.
19. Diekema, D. J., Messer, S. A., Brueggemann, A. B., Coffman, S. L., Doern, G. V., Herwaldt, L. A. & Pfaller, M. A. (2002). Epidemiology of candidemia: 3-year results from the emerging infections and the epidemiology of Iowa organisms study. J Clin Microbiol 40, 1298-1302.
20. Dodgson, A. R., Pujol, C., Denning, D. W., Soll, D. R. & Fox, A. J. (2003). Multilocus sequence typing of Candida glabrata reveals geographically enriched clades. J Clin Microbiol 41, 5709-5717.
21. Feil, E. J., Li, B. C., Aanensen, D. M., Hanage, W. P. & Spratt, B. G. (2004). eBURST: inferring patterns of evolutionary descent among clusters of related bacterial genotypes from multilocus sequence typing data. J Bacteriol 186, 1518-1530.
22. Fotedar, R. & Al Hedaithy, S. S. A. (2003). Candida dubliniensis at a university hospital in Saudi Arabia. J Clin Microbiol 41, 1907-1911.
23. Hajjeh, R. A., Sofair, A. N., Harrison, L. H., Lyon, G. M., Arthington-Skaggs, B. A., Mirza, S. A., Phelan, M., Morgan, J., Lee-Yang, W. & other authors (2004). Incidence of bloodstream infections due to Candida species and in vitro susceptibilities of isolates collected from 1998 to 2000 in a population-based active surveillance program. J Clin Microbiol 42, 1519-1527.
24. Kao, A. S., Brandt, M. E., Pruitt, W. R., Conn, L. A., Perkins, B. A., Stephens, D. S., Baughman, W. S., Reingold, A. L., Rothrock, G. A. & other authors (1999). The epidemiology of candidemia in two United States cities: results of a population-based active surveillance. Clin Infect Dis 29, 1164-1170.
25. Kibbler, C. C., Seaton, S., Barnes, R. A., Gransden, W. R., Holliman, R. E., Johnson, E. M., Perry, J. D., Sullivan, D. J. & Wilson, J. A. (2003). Management and outcome of bloodstream infections due to Candida species in England and Wales. J Hosp Infect 54, 18-24.
26. Laupland, K. B., Gregson, D. B., Church, D. L., Ross, T. & Elsayed, S. (2005). Invasive Candida species infections: a 5 year population-based assessment. J Antimicrob Chemother 56, 532-537.
27. Levy, I., Rubin, L. G., Vasishtha, S., Tucci, V. & Sood, S. K. (1998). Emergence of Candida parapsilosis as the predominant species causing candidemia in children. Clin Infect Dis 26, 1086-1088.
28. Marchetti, O., Bille, J., Fluckiger, U., Eggimann, P., Ruef, C., Garbino, J., Calandra, T., Glauser, M. P., Tauber, M. G. & Pittet, D. (2004). Epidemiology of candidemia in Swiss tertiary care hospitals: secular trends, 1991-2000. Clin Infect Dis 38, 311-320.
29. Marco, F., Danes, C., Almela, M., Jurado, A., Mensa, J., de la Bellacasa, J. P., Espasa, M., Martinez, J. A. & de Anta, M. T. J. (2003). Trends in frequency and in vitro susceptibilities to antifungal agents, including voriconazole and anidulafungin, of Candida bloodstream isolates. Results from a six-year study (1996-2001). Diagn Microbiol Infect Dis 46, 259-264.
30. McCullough, M. J., Clemons, K. V. & Stevens, D. A. (1999). Molecular and phenotypic characterization of genotypic Candida albicans subgroups and comparison with Candida dubliniensis and Candida stellatoidea. J Clin Microbiol 37, 417-421.
31. McNeil, M. M., Nash, S. L., Hajjeh, R. A., Phelan, M. A., Conn, L. A., Plikaytis, B. D. & Warnock, D. W. (2001). Trends in mortality due to invasive mycotic diseases in the United States, 1980-1997. Clin Infect Dis 33, 641-647.
32. Meis, J. F. G. M., Ruhnke, M., de Pauw, B. E., Odds, F. C., Siegert, W. & Verweij, P. E. (1999). Candida dubliniensis candidemia in patients with chemotherapy-induced neutropenia and bone marrow transplantation. Emerg Infect Dis 5, 150-153.
33. Morgan, J. (2005). Global trends in candidemia: review of reports from 1995-2005. Curr Infect Dis Rep 7, 429-439.
34. NCCLS (2002). Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts, approved standard, 2nd edn. Wayne, PA: National Commmittee for Clinical Laboratory Standards.
35. Odds, F. C. (1988). Candida and Candidosis, 2nd edn. London: Bailliere Tindall.
36. Odds, F. C. & Bernaerts, R. (1994). CHROMagar Candida, a new differential isolation medium for presumptive identification of clinically important Candida species. J Clin Microbiol 32, 1923-1929.
37. Odds, F. C., Vranckx, L. & Woestenborghs, F. (1995). Antifungal susceptibility testing of yeasts: evaluation of technical variables for test automation. Antimicrob Agents Chemother 39, 2051-2060.
38. Odds, F. C., Davidson, A. D., Jacobsen, M. D., Tavanti, A., Whyte, J. A., Kibbler, C. C., Ellis, D. H., Maiden, M. C. J., Shaw, D. J. & Gow, N. A. R. (2006). Candida albicans strain maintenance, replacement and microvariation demonstrated by multilocus sequence typing. J Clin Microbiol 44, 3647-3658.
39. Odds, F. C., Bougnoux, M.-E., Shaw, D. J., Bain, J. M., Davidson, A. D., Diogo, D., Jacobsen, M. D., Lecomte, M., Li, S.-Y. & other authors (2007). Molecular phylogenetics of Candida albicans. Eukaryot Cell 6, 1041-1052.
40. Pappas, P. G., Rex, J. H., Sobel, J. D., Filler, S. G., Dismukes, W. E., Walsh, T. J. & Edwards, J. E. (2004). Guidelines for treatment of candidiasis. Clin Infect Dis 38, 161-189.
41. Pemán, J., Canton, E. & Gobernado, M. (2005). Epidemiology and antifungal susceptibility of Candida species isolated from blood: results of a 2-year multicentre study in Spain. Eur J Clin Microbiol Infect Dis 24, 23-30.
42. Pfaller, M. A., Diekema, D. J., Jones, R. N., Messer, S. A. & Hollis, R. J. (2002). Trends in antifungal susceptibility of Candida spp. isolated from pediatric and adult patients with bloodstream infections: SENTRY Antimicrobial Surveillance Program, 1997 to 2000. J Clin Microbiol 40, 852-856.
43. Pfaller, M. A., Diekema, D. J. & Sheehan, D. J. (2006). Interpretive breakpoints for fluconazole and Candida revisited: a blueprint for the future of antifungal susceptibility testing. Clin Microbiol Rev 19, 435-447.
44. Poikonen, E., Lyytikainen, O., Anttila, V. J. & Ruutu, P. (2003). Candidemia in Finland, 1995-1999. Emerg Infect Dis 9, 985-990.
45. Price, M. F., Larocco, M. T. & Gentry, L. O. (1994). Fluconazole susceptibilities of Candida species and distribution of species recovered from blood cultures over a 5-year period. Antimicrob Agents Chemother 38, 1422-1424.
46. Pujol, C., Pfaller, M. & Soll, D. R. (2002). Ca3 fingerprinting of Candida albicans bloodstream isolates from the United States, Canada, South America, and Europe reveals a European clade. J Clin Microbiol 40, 2729-2740.
47. Rangel-Frausto, M. S., Wiblin, T., Blumberg, H. M., Saiman, L., Patterson, J., Rinaldi, M., Pfaller, M., Edwards, J. E., Jarvis, W. & other authors (1999). National Epidemiology of Mycoses Survey (NEMIS): variations in rates of bloodstream infections due to Candida species in seven surgical intensive care units and six neonatal intensive care units. Clin Infect Dis 29, 253-258.
48. Rex, J. H., Nelson, P. W., Paetznick, V. L., Lozanochiu, M., Espinelingroff, A. & Anaissie, E. J. (1998). Optimizing the correlation between results of testing in vitro and therapeutic outcome in vivo for fluconazole by testing critical isolates in a murine model of invasive candidiasis. Antimicrob Agents Chemother 42, 129-134.
49. San Miguel, L. G., Cobo, J., Otheo, E., Sanchez-Sousa, A., Abraira, V. & Moreno, S. (2005). Secular trends of candidemia in a large tertiary-care hospital from 1988 to 2000: emergence of Candida parapsilosis. Infect Control Hosp Epidemiol 26, 548-552.
50. Sandven, P. (2000). Epidemiology of candidemia. Rev Iberoam Micol 17, 73-81.
51. Sandven, P., Bevanger, L., Digranes, A., Haukland, H. H., Mannsaker, T. & Gaustad, P. (2006). Candidemia in Norway (1991 to 2003): results from a nationwide study. J Clin Microbiol 44, 1977-1981.
52. Soll, D. R. & Pujol, C. (2003). Candida albicans clades. FEMS Immunol Med Microbiol 39, 1-7.
53. Stone, H. H., Kold, L. D., Currie, C. A., Geheber, C. E. & Cuzzell, J. Z. (1974). Candida sepsis: pathogenesis and principles of treatment. Ann Surg 179, 697-711.
54. Tavanti, A., Davidson, A. D., Gow, N. A. R., Maiden, M. C. J. & Odds, F. C. (2005a). Candida orthopsilosis and Candida metapsilosis spp. nov to replace Candida parapsilosis groups II and III. J Clin Microbiol 43, 284-292.
55. Tavanti, A., Davidson, A. D., Fordyce, M. J., Gow, N. A. R., Maiden, M. C. J. & Odds, F. C. (2005b). Population structure and properties of Candida albicans, as determined by multilocus sequence typing. J Clin Microbiol 43, 5601-5613.
56. Tavanti, A., Davidson, A. D., Johnson, E. M., Maiden, M. C. J., Shaw, D. J., Gow, N. A. R. & Odds, F. C. (2005c). Multilocus sequence typing for differentiation of strains of Candida tropicalis. J Clin Microbiol 43, 5593-5600.
57. Tortorano, A. M., Peman, J., Bernhardt, H., Klingspor, L., Kibbler, C. C., Faure, O., Biraghi, E., Canton, E., Zimmermann, K. & other authors (2004). Epidemiology of candidaemia in Europe: results of 28-month European Confederation of Medical Mycology (ECMM) hospital-based surveillance study. Eur J Clin Microbiol Infect Dis 23, 317-322.
58. Trick, W. E., Fridkin, S. K., Edwards, J. R., Hajjeh, R. A. & Gaynes, R. P. (2002). Secular trend of hospital-acquired candidemia among intensive care unit patients in the United States during 1989-1999. Clin Infect Dis 35, 627-630.
59. Vazquez, J. A. & Sobel, J. D. (2003). Candidiasis. In Clinical Mycology, pp. 143-187. Edited by W. E. Dismukes, P. G. Pappas & J. D. Sobel. Oxford: Oxford University Press.